The US Food and Drug Administration (FDA) has cleared Syneron Medical’s new elos Plus multi-platform device.
The new elos Plus device, which uses the company’s proprietary elos technology of optical energy and bipolar radiofrequency, features an intuitive 15in touchscreen, providing unparalleled ease-of-use through its simple, guided treatment modes for all applications.
The elos system can be customised or upgraded using a full range of up to eight in-demand aesthetic applicators, including the company’s Sublative and Sublime applicators.
Syneron CEO, Louis P Scafuri, said that the vision for the elos Plus was to bring to market a comprehensive multi-platform system that out-delivers the competition in performance, reliability and scalability.
"Our new system was designed to grow with any size practice and caters to a diverse patient population," Scafuri added.
"It has the capacity to deliver a full range of aesthetic treatments and is equipped with the most advanced features for optimum speed, safety and performance.
"We believe elos Plus will appeal to a broad range of customers and allow them to customise their investment to meet the demand of their individual practice."
Syneron, an aesthetic device company, said the elos Plus system can be used in any aesthetic practices, when equipped with its proprietary Sublative iD, Active Dermal Monitoring and Intelligent Feedback system (IFS).
South Coast Dermatology Institutes medical director and dermatologist, Vince Afsahi, said: "The intuitive and interactive user interface of the elos Plus improves user experience, while the additional safety measures such as the IFS, which is now available on all applications, ensures maximum treatment delivery without compromising patient safety or comfort."